Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
Status:
Terminated
Trial end date:
2019-12-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if ficlatuzumab when combined with cytarabine, a standard
treatment for AML, is safe to give to patients and to determine the best dose to give. The
study doctors want to see what effects, good and/or bad, the study drug has on subjects and
their AML. The study will look at what side effects subjects may have and how subjects feel
after receiving the study drug.
Phase:
Phase 1
Details
Lead Sponsor:
C. Babis Andreadis
Collaborators:
AVEO Pharmaceuticals, Inc. Gateway for Cancer Research University of California, San Francisco